Document Detail

Increased levels of serum interleukin-18 in Graves' disease.
MedLine Citation:
PMID:  11041460     Owner:  NLM     Status:  MEDLINE    
We have previously reported that serum soluble interleukin-2 receptor (sIL-2R) and IL-12 levels were significantly increased in hyperthyroid Graves' disease. In this study, we investigated serum IL-18 levels in patients with either Graves' disease or Hashimoto's thyroiditis. The serum IL-18 levels in Graves' disease were significantly increased in the hyperthyroid state and were decreased during treatment with methimazole or propylthiouracil. On the other hand, the levels in Hashimoto's thyroiditis in the hypothyroid state showed no significant differences from those in healthy subjects. When liothyronine sodium was administered orally to healthy subjects, serum IL-18 levels were not changed. Positive correlations between serum IL-18 and IL-12, IL-12 and sIL-2R, and sIL-2R and IL-18 levels were noted in Graves' disease. These results suggest that Th1 cytokines might play an important regulatory role in Graves' disease.
S Miyauchi; B Matsuura; M Onji
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Thyroid : official journal of the American Thyroid Association     Volume:  10     ISSN:  1050-7256     ISO Abbreviation:  Thyroid     Publication Date:  2000 Sep 
Date Detail:
Created Date:  2001-01-17     Completed Date:  2001-02-01     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  9104317     Medline TA:  Thyroid     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  815-9     Citation Subset:  IM    
The Third Department of Internal Medicine, School of Medicine, Ehime University, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antithyroid Agents / therapeutic use
Graves Disease / blood*,  drug therapy
Interleukin-18 / blood*
Methimazole / therapeutic use
Middle Aged
Propylthiouracil / therapeutic use
Thyroiditis, Autoimmune / blood
Triiodothyronine / diagnostic use
Reg. No./Substance:
0/Antithyroid Agents; 0/Interleukin-18; 51-52-5/Propylthiouracil; 60-56-0/Methimazole; 6893-02-3/Triiodothyronine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor...
Next Document:  Hypothyroidism and aging: the Rosses' survey.